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Abstract
Background/Aims: Combinations of treatments that have
already received regulatory approval can offer additional
benefit over each of the treatments individually. However,
trials of these combinations are lower priority than those
that develop novel therapies, which can restrict funding,
timelines and patient availability. This paper develops
a novel trial design to facilitate the evaluation of new
combination therapies. This trial design combines elements
of phase II and phase III trials to reduce the burden of
evaluating combination therapies, whilst also maintaining
a feasible sample size. This design was developed for
a randomised trial that compares the properties of three
combination doses of ketamine and dexmedetomidine,
given intranasally, to ketamine delivered intravenously for
children undergoing a closed reduction for a fracture or
dislocation.
Methods: This trial design uses response adaptive
randomisation to evaluate different dose combinations
and increase the information collected for successful
novel drug combinations. The design then uses Bayesian
dose-response modelling to undertake a comparativeeffectiveness analysis for the most successful dose
combination against a relevant comparator. We used
simulation methods to determine the thresholds for
adapting the trial and making conclusions. We also used
simulations to evaluate the probability of selecting the
dose combination with the highest true effectiveness, the
operating characteristics of the design and its Bayesian
predictive power.
Results: With 410 participants, 5 interim updates of
the randomisation ratio and a probability of effectiveness
of 0.93, 0.88 and 0.83 for the three dose combinations,
we have an 83% chance of randomising the largest
number of patients to the drug with the highest probability
of effectiveness. Based on this adaptive randomisation
procedure, the comparative effectiveness analysis has a
Prepared using sagej.cls [Version: 2017/01/17 v1.20]

type I error of less than 5% and a 93% chance of
correctly concluding non-inferiority when the probability
of effectiveness for the optimal combination therapy is 0.9.
In this case, the trial has a 77% chance of meeting its dual
aims of dose finding and comparative effectiveness. Finally,
the Bayesian predictive power of the trial is over 90%.
Conclusions: By simultaneously determining the optimal dose and collecting data on the relative effectiveness
of an intervention, we can minimise administrative burden
and recruitment time for a trial. This will minimise the
time required to get effective, safe combination therapies
to patients quickly. The proposed trial has high potential
to meet the dual study objectives within a feasible overall
sample size.
Keywords Response adaptive trial, Non-inferiority trial,
Bayesian Analysis, Clinical Trial Design

Introduction
Investigator-initiated trials, where clinician investigators
undertake their own trials, 1 are key to expanding the use
of therapies that have received regulatory approval. 2 One
key expansion develops therapies that combine two or
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more currently available interventions to improve outcomes
compared to either treatment alone. 3–5 To develop
these novel combination therapies, we must determine
the optimal combination and evaluate its comparative
effectiveness to the current standard of care.
In standard drug development processes, these two aims
require two trials; a phase II trial to determine the optimal
dose combination and a phase III trial to evaluate the
comparative effectiveness. 6 However, initiating a trial is
time and resource intensive, 7 especially when separate
funding must be sought for each phase. Thus, trial designs
that incorporate both of these elements, whilst maintaining
a reasonable level of patient recruitment, can improve the
efficiency of the trial process. 8
Seamless phase II/III trials that move between the
investigative Phase II and the confirmatory Phase III
are the most common type of adaptive trials 9 as
they are more efficient than two independent trials. 10
These trials typically combine two distinct phases,
where successful treatments are ‘taken forward’ from
Phase II to Phase III. 8 Thus, statistical designs are
available to select the optimal treatment from a set of
alternatives before undertaking a comparative effectiveness
analysis between the optimal treatment and a relevant
comparator. 11–13 In particular, Wang et al. develop a twostage design that uses a non-inferiority framework for
the final comparative effectiveness analysis with normally
distributed outcomes. 14 They highlight that extending these
two-stage designs to a non-inferiority framework is nontrivial due to the complex null hypothesis. 14 Elsewhere,
Kimani et al. developed a seamless design that incorporated
dose selection based on safety and efficacy using Bayesian
methods and a final comparative analysis based on
frequentist hypothesis testing. 15
The Ketodex trial, an investigator-initiated trial looking
at treatments for procedural sedation within a paediatric
emergency department, 16 aims to determine the optimal
dose combination among three alternatives and assess
whether it is non-inferior to the standard of care using a
binary outcome. Thus, we developed a novel trial design
that uses response adaptive randomisation, 17 dose response
modelling for dose combinations, 18 and a comparative
effectiveness analysis from a non-inferiority perspective
with binary outcomes. In contrast to the currently available
methods, we used a Bayesian framework for both the dose
selection and comparative effectiveness analysis. This trial
also avoids a formal separation between the two study
phases to maximise the time available to assess the relative
efficacy of the different dose combinations.
We used Bayesian response adaptive randomisation to
increase the expected allocation of patients to the optimal
dose combination. 17,19 While adaptive randomisation in
multi-arm trials can lead to low probabilities of selecting
Prepared using sagej.cls
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the true optimal treatment, 20 we found that the proposed
adaptive randomisation scheme yielded a high probability
of selecting the correct optimal treatment, based on
our assumptions. Using dose response modelling for
the different combination therapies then ensures that
all participant data is used in the final comparative
analysis. 18 Typically, the analysis of a seamless trial
requires adjustments to ensure valid construction of
confidence intervals and p-values. 21 However, we avoided
this requirement as all inference was proposed from a
Bayesian perspective. 22
This paper presents our novel trial design and the
simulation scenarios used to determine decision thresholds
for the trial adaptions and the comparative analyses. 23
All thresholds were chosen to ensure the trial had good
frequentist operating characteristics and a high chance of
detecting the true optimal treatment. 22 We also introduced
a novel framework for drawing conclusions based on
the study data where an inconclusive trial outcome
suggests additional data should be collected. Finally, we
demonstrated that this design has high Bayesian predictive
power.

The Ketodex Trial
Procedural sedation and analgesia (PSA) is used to
facilitate the realignment of a fractured or dislocated
limb without surgery in children (known as a closed
reduction). 24,25 Intravenous (IV) ketamine is often used
to provide PSA. 24 However, IV insertion is distressing
to children and their families and is often technically
challenging. 26 Thus, an alternative administration method
would be preferred, e.g. intranasal (IN) administration.
There is limited evidence that a combination of ketamine
and dexmedetomidine (ketodex) given intranasally may
offer adequate sedation. 27,28 However, this combination has
not been trialled in patients undergoing a closed reduction
and so the Ketodex trial aims to:
(i) determine a suitable combination of IN ketodex and
(ii) compare the efficacy of IN ketodex (novel combination therapy) to IV ketamine (standard of care).
As IN delivery of sedative agents is preferable to IV
insertion, the Ketodex trial considers whether IN ketodex
is non-inferior to IV ketamine.
The Ketodex trial has a binary primary outcome where
“success” is defined as a patient who is adequately sedated
throughout the closed reduction procedure. Adequate
sedation is defined as
(i) A Paediatric Sedation State Score (PSSS) of 2 or 3
for the duration of the procedure; 29
(ii) No additional medication given for the purposes of
sedation during the procedure;
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(iii) The patient does not actively resist, cry or require
physical restraint to complete the procedure.
Patients, aged 4 - 17 (maximum 70kg), are enrolled if the
physician expects to complete the procedure within five
minutes. The primary outcome is measured by blinded
video assessors within 24 hours of enrolment and will,
thus, be used to assess the efficacy of the different ketodex
combinations and the relative effectiveness of IN ketodex to
IV ketamine. Clinical expertise based on a recent systematic
review, 30 selected three dose combinations for IN ketodex
for the trial:
1. A single dose of ketamine at 2 mg/kg combined with
dexmedetomidine at 4 mcg/kg (2-4 ketodex)
2. A single dose of ketamine at 3 mg/kg combined with
dexmedetomidine at 3 mcg/kg (3-3 ketodex)
3. A single dose of ketamine at 4 mg/kg combined with
dexmedetomidine at 2 mcg/kg (4-2 ketodex)
Full details of the trial conduct and outcomes are in the trial
protocol. 16

Methods
Figure 1 is a graphical representation of our novel
trial design, consisting of three key steps; adaptive
randomisation, dose response modelling and a comparative
effectiveness analysis.

Overall Sample Size
The overall sample size was determined based on pragmatic
concerns and the Average Length Criterion (ALC). 31,32
ALC selects the smallest sample size for which the posterior
credible interval has an average length below some fixed
constant ζ, to be specified. This trial design controlled
the average length of the high-density posterior credible
interval of the difference in effectiveness between the
standard of care and the novel combination. We also used
the ALC to determine the appropriate randomisation ratio
between the novel combinations and the standard of care.
For this overall sample size calculation, we did not consider
any adaptive elements. However, our simulations ensured
well-controlled error rates conditional on this sample size
and the proposed adaptive design.

Response-Adaptive Randomisation
We fixed the proportion of patients receiving the standard
of care, to ensure enough data for the comparative
effectiveness analysis, 20 and applied response-adaptive
randomisation to increase the number of participants
receiving effective dose combinations. 17 Practically, this
required a two-stage randomisation procedure where
participants are initially randomised to either the standard
Prepared using sagej.cls
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of care or the dose combinations. We define R0 as
the proportion of participants randomised to receive the
standard of care and R1 = 1 − R0 as the proportion of
participants randomised to receive the dose combinations.
Participants who receive the dose combinations are then
further randomised to receive a specific combination in a
randomisation ratio that is updated at each interim analysis
(first panel in Figure 1). Note that, to maintain blinding
in the Ketodex trial, all participants are randomised to a
dose combination, even if they receive the standard of care
and the dose combination would be between two placebo
agents.
Formally, in the second randomisation step, the
randomisation ratio across the different dose combinations
i = 1, 2, 3 is set separately for each trial period j =
1, . . . , J, where J is the number of phases for the adaptive
randomisation (6 in Figure 1). We denote the proportion of
participants randomised to dose combination i, given that
they are receiving the active combination, in trial period
j, ri,j and, thus, the overall proportion of participants
randomised to dose combination i in period j is R1 × ri,j .
We set ri,j equal to the probability that dose combination
i is optimal given the available evidence;


ri,j = Prob pi = max{pi }
i

where pi is the probability of success for the dose
combination i. The posterior distribution of pi will be
obtained conditional on the data collected in trial periods
1 to j. We use the same prior distribution for pi , i =
1, . . . , 3 so ri,1 = 13 . To avoid randomising a small number
of participants to a single arm, 20 we determined a value γ
such that we set ri,j = 0 when ri,j ≤ γ. We then adjust the
P3
values of ri,j so i=1 ri,j = 1. Note that all trial data will
be included in the final analysis and a dose combination can
be reinstated in the randomisation scheme even if it was
excluded previously (Figure 1, trial periods 4 and 5).
The practicalities of the Ketodex trial meant that
the second step randomisation is undertaken without
knowledge of the treatment group assignment from the first
randomisation. This means that we cannot fix the exact
proportion of participants receiving dose combination i in
period j to R1 × ri,j . Therefore, assuming that the number
of participants to be enrolled in trial period j is Nj , the
number of participants randomised to each active dose
combination i will be a random variable
Mi,j ∼ Binomial(Nj ri,j , R1 ).

Dose Response Modelling
The primary effectiveness analysis will use a dose response
model to estimate the probability of success for each of
the three dose combinations. 15,18 To achieve this, note that
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Figure 1. A graphical representation of the proposed trial design. The trial design and analysis consists of three key steps. We
use response adaptive randomisation for the R1 proportion of patients receiving the novel combination (represented in the top
half of the Figure). The R0 proportion of patients who receive the standard of care are also randomised to a combination of
placebo agents to maintain blinding. Within the adaptive randomisation section, ri,j is the proportion of patients randomised to
dose combination i in trial period j . Further, if ri,j is less than a threshold γ , no patients are randomised to this combination in
trial period j . In the second step, we use Bayesian dose response modelling to determine the posterior distribution of the
(2)
probability of success for each dose combination (pi , i = 1, 2, 3). The optimal treatment (probability of success denoted pD ) is
the treatment with the maximum expected probability of success, represented by the vertical lines in the top of the second panel.
Finally, we compare the effectiveness of the dose combination to the effectiveness of the standard of care (probability of success
denoted pC ) by computing the probability that the difference (d) in effectiveness is below a given threshold (η ). Conclusions
following the trial are made based on thresholds λ1 and λ2 , chosen by simulation. Notation in bold is determined using
simulation methods.

participants who are not adequately sedated can either be
over-sedated (PSSS score of 0 or 1) or under-sedated (PSSS
score of 4 or 5). 29 We assume that the probability of overand under-sedation can each be modelled with a monotonic
log-logistic dose response model based on expert opinion.
We then use a multinomial distribution to make inferences
about the probability of adequate sedation.
Let Xi , i = 1, 2, 3, be a 3-vector containing the number
of patients who experience
PJunder, adequate and oversedation from the Ni = j=1 Mi,j participants who
receive dose i;
Xi ∼ Multinomial(Ni , pi ),
(1)

(2)

(3)

with pi = c(pi , pi , pi )0 ,
(1)

logit(pi ) = β0 + β1 log(Ai ) + β2 log(Bi ),
(3)

logit(pi ) = βa + βb log(Ai ) + βc log(Bi ),
and Ai is dose for drug A (ketamine) and Bi is the
dose for drug B (dexmedetomidine). We have not included
interaction terms as they cannot be reliably estimated and
Prepared using sagej.cls

models without interactions perform well in dose finding
studies. 33
Using these dose response models, we can determine
(2)
the posterior for pi , i = 1, 2, 3, the probability of
adequate sedation for each dose combination. The optimal
dose combination is the combination with the maximum
(2)
expected value of pi . In Figure 1, the expected values
(2)
of pi are shown using vertical lines, with the highest
expected value associated with the first dose combination.
For the comparative effectiveness analysis, we denote the
probability of a success for the optimal dose combination
(2)
as pD , i.e., in Figure 1, pD = p1 .

Comparative Effectiveness Analysis
The comparative effectiveness analysis compares the
probability of success for standard of care, pC , to pD . In a
Bayesian framework, we compute the posterior distribution
of d = pC − pD and then calculate the probability that
d is greater than a pre-specified value η; y = P (d ≥ η).
A superiority trial would set η = 0 but, the Ketodex trial
aims to determine whether IN ketodex is non-inferior to
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IV ketamine and, therefore, η is the non-inferiority margin
of 0.178. This non-inferiority margin is the average from
the responses of 204 clinicians in surveys undertaken by
the Ketodex team. Small values of y are evidence of noninferiority.
The proposed trial has three potential outcomes (Figure
1):
1. The optimal dose combination is superior/noninferior,
2. The trial is inconclusive or,
3. The standard of care is superior.
The trial conclusion is made using two thresholds λ1 and
λ2 , chosen by simulation to control the trial errors rates,
as required for Bayesian designs. 22 Specifically, if y ≤ λ1
then we conclude that the optimal dose combination is
superior/non-inferior to the standard of care. If y ≥ λ2 , then
we conclude that the standard of care is superior to the
optimal dose combination. As λ1 + λ2 < 1, any values of
y between λ1 and λ2 will be deemed inconclusive, i.e.,
the current data are insufficient to determine whether the
novel combination or the standard of care is superior. This
conclusion encourages the collection of more data to deliver
definitive conclusions.

Simulation Scenarios
We used simulations to develop and evaluate our trial
design. To achieve this, we used four different simulation
settings to:
1. Evaluate the ALC to determine the overall sample
size and value of R0 ; the proportion of participants
randomised to the standard of care.
2. Determine the value of γ; the threshold under which
we drop a dose combination from the randomisation
procedure.
3. Determine the values of λ1 and λ2 ; the thresholds
for concluding non-inferiority of the optimal dose
combination or the standard of care.
4. Compute the predictive power of the trial.
These simulation scenarios were undertaken sequentially,
i.e., the overall sample size was determined and then used
as the sample size throughout the remaining simulation
scenarios. The following sections outline the parameters of
these four simulation settings and the criteria used draw
conclusions from each simulation for the Ketodex trial.
Determining the Overall Sample Size We set ζ = 0.07

and controlled the length of the 95% highest density
posterior credible interval. The value for ζ represents a
posterior credible interval that is six times shorter than
the prior credible interval and was chosen considering the
budget and time constraints that limited our maximum
recruitment. 32
Prepared using sagej.cls
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ALC determined the overall trial sample size and R0 ,
the proportion of participants randomised to the standard
of care. We considered four values for R0 , 0.2, 0.3, 0.4 and
0.5, and computed the ALC for each R0 for sample sizes
increasing in increments of 10 from 350 to 500. We selected
the smallest sample size that respects the ALC and then, for
that sample size, we selected the value of R0 that leads to
the most balanced trial, provided the ALC is respected.
For each sample size and value of R0 , we simulated
2000 datasets from the prior-predictive distribution of the
data, using the priors defined below. For each dataset, we
obtained 2000 simulations from the posterior distribution
of pC and pD and computed the highest density posterior
95% credible interval. 34 We estimated their average length
for each sample size and value of R0 across all 2000 priorpredictive datasets.
Determining γ for the adaptive randomisation We used

simulations to determine the value of γ, the threshold for
dropping a given dose combination from randomisation in
a specific trial period. We considered values between 0.05
and 0.3, increasing in increments of 0.05, with 0.3 chosen
as the maximum because an even randomisation ratio would
have 0.33 randomised to each arm. We fixed the probability
of adequate sedation for the three dose combinations at
0.93, 0.88 and 0.83, as 0.93 is the success rate seen in
a previous trial of IN Ketodex 28 . We then calculated
the number of participants randomised to each treatment
option for each value of γ. Across 7000 simulations,
we estimated the probability of randomising the highest
number of participants to the dose with probability of
adequate sedation equal to 0.93. We selected the value of
γ that maximises this probability. If two values for γ gave
the same probability, we chose the smallest threshold γ.
This maximises the amount of information collected for the
optimal treatment, if the incorrect optimal treatment were
selected.
We used 7000 simulations as it gives a greater than
99% chance of estimating the probability of 0.8 to 2
decimal places, the accuracy chosen for all analyses in this
manuscript.
Thresholds for Comparative Effectiveness Analysis

Based on the adaptive randomisation scheme finalised in
the previous section, we used simulation to determine
the decision thresholds for the comparative effectiveness
analysis, λ1 and λ2 . As λ1 controls the type I error of
the trial, we set the probability of adequate sedation for
IN Ketodex pC = 0.97, 35 and the probability of adequate
sedation for the optimal dose combination pD = pC − η =
0.792. We then selected λ1 such that 5% of the trials
incorrectly conclude non-inferiority. For λ2 , we set pD =
0.78, and undertook the same trial simulation process,
specifying that 50% of the simulated trials should declare
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superiority for the standard of care. We set 3-3 ketodex
as the optimal treatment, based on expert guidance, and
the probability of adequate sedation of 4-2 ketodex to
pD − 0.05 and 2-4 ketodex as pD − 0.1. Expert guidance
specified that high doses of dexmedetomidine could lead
to over sedation. Thus, we assumed that the proportion
of people that were over-sedated, among those who were
inadequately sedated, was 0.01, 0.1 and 0.2 for ketodex 4-2,
3-3 and 2-4, respectively. Finally, we simulated 7000 trials
with the proposed comparative effectiveness analysis using
7000 posterior simulations for pi , i = 1, 2, 3, and pC for
each trial.
Finally, to understand the design characteristics
further, we evaluated the probability of each
trial outcome, for 8 different values of pD ;
pD = 0.93, 0.9, 0.87, 0.85, 0.83, 0.792, 0.78 and 0.75,
using the specified values of λ1 and λ2 . Table 1 outlines
the values set for each probability of interest in all these
scenarios.
Bayesian Predictive Power We calculated the expected

probability of a conclusive trial, i.e., concluding superiority
of the novel combination or the standard of care, using
Bayesian predictive power. We took 2000 simulations from
the prior predictive distributions of pC and pD , using the
priors outlined below. We considered three scenarios where
we varied the relative risk of adequate sedation for the three
dose combinations relative to our prior beliefs about pD
(outlined in Table 2). Scenario A set the relative risk to
0.9, 0.95 and 1 for 4-2, 2-4 and 3-3 ketodex, respectively.
Similarly, Scenario B used 0.95, 0.98 and 1 and Scenario C
used 0.95, 1 and 1.05. We assumed that the proportion of
inadequately sedated patients who were over-sedated was
0.01, 0.1 and 0.2 for 4-2, 3-3 and 2-4 ketodex, respectively.
We used 2000 posterior simulations for pi , i = 1, 2, 3, and
pC to perform the comparative effectiveness analysis for
each prior predictive sample.

Prior Specification
We specified priors for pC , the probability of success for the
standard of care, β0 , β1 , β2 , βa , βb , and βc , the parameters
of the log-logistic dose-response models for under- and
over-sedation. For the prior predictive analyses, we also
specified a prior for pD , the probability of success for
the optimal dose combination, directly. We used either
published evidence or minimally informative priors.
For IV ketamine, Kannikeswaran et al. had a 97%
success rate with ketamine dosed at 1.5 mg/kg, as proposed
in the Ketodex trial. 35 To account for differences between
this trial and the Ketodex trial, we down-weighted this
information to an effective sample size of 16;
pC ∼ Beta(15.6, 0.44).
Prepared using sagej.cls

Bhat et al. published a trial in which 2 out of 27 participants
were inadequately sedated with IN Ketodex dosed at 1
mg/kg of ketamine and 2 µg/kg of dexmedetomidine. 28
To account for substantial differences between the two
trials, including in dosing and the setting, we discount this
information to an effective sample size of 6.5;
pD ∼ Beta(6.25, 0.25).
The effective sample size of the prior for pD means that a
priori there is a 90% chance that IN ketodex is non-inferior
to IV ketamine, using the non-inferiority margin η = 0.178.
For the regression coefficients, we used non-central
Student t-distributions with precision 0.001 and degrees of
freedom 1. 36 We set the mean for β1 , β2 , βb and βc to be 0,
as we have minimal information on the dose response. For
β0 and βa , we set their means such that 5% of participants
are expected to be under-sedated and 2% of participants
are expected to be over-sedated. Thus, the prior means of
(2)
pi , i = 1, 2, 3 are 0.93, the success rate observed in the
literature. 28

Results
Average Length Criterion
Figure 2 displays the results from the ALC analysis. The
ALC is respected with a sample size of 410 and R0 =
0.4. For all sample sizes, R0 = 0.4 results in the shortest
credible intervals. With this sample size, we structured the
interim analyses using pragmatic concerns. The first interim
analysis will take place after an expected enrolment of 30
participants for each dose combination to ensure sufficient
data is collected before changing the randomisation ratio. 37
Thus, the first interim analysis will take place once 150
participants have been enrolled. Further updates of the
randomisation ratio will take place at intervals of 50
participants, i.e., at 150, 200, 250, 300, 350, before the final
comparative effectiveness analysis at 410.

Adaptive Randomisation: Choosing γ
Table 3 displays the probability of randomising the
highest number of people to the true optimal dose
combination. This probability is maximised when γ =
0.05, 0.2, 0.25, 0.3, with an 83% chance of randomising the
most people to the optimal treatment. Thus, we chose the
smallest value; γ = 0.05 and expect to enrol 137 patients to
the optimal treatment with an 95% interval between 56 and
190.

Comparative Effectiveness Analysis: Choosing
λ1 and λ2
Based on the overall sample size and the values for R0 and
γ, λ1 = 0.037 ensures a type I error of 5% size and λ2 =

Heath, et al.
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Scenario
Number
1
2
3
4
5
6
7
8

Probability of Adequate
Sedation
3-3
4-2
2-4
0.93
0.88
0.83
0.90
0.85
0.80
0.87
0.83
0.77
0.85
0.80
0.75
0.83
0.78
0.73
0.792 0.742
0.692
0.78
0.73
0.68
0.75
0.70
0.65

Probability of
Sedation
3-3
4-2
0.007 0.0012
0.010 0.0015
0.013 0.0017
0.015 0.0020
0.017 0.0022
0.021 0.0026
0.022 0.0027
0.025 0.0030

Over-

Number of Non-Inferior Dose
Combinations

2-4
0.034
0.040
0.046
0.050
0.054
0.062
0.064
0.070

3
3
2
2
1
0
0
0

Table 1. The values set for the probability of adequate and over-sedation in the eight scenarios considered to assess the
operating characteristics of the Ketodex trial. The probabilities are given for each of the three dose combinations 3-3 ketodex, 4-2
ketodex and 2-4 ketodex. In each scenario, we highlight the number of dose combinations that are non-inferior to IV ketamine.

2-4
0.95
0.98
1

0.080

4-2
0.9
0.95
0.95

Table 2. The scenarios considered to estimate the Bayesian
predictive power of the Ketodex trial. We specified the relative
risk of adequate sedation compared to our prior beliefs about
the probability of adequate sedation. Secondly, we specified
the proportion of over-sedated participants, among those who
were inadequately sedated, for each of the three dose
combinations. In this case, using a prior distribution for the
probability of adequate sedation means that we cannot display
the probability of over-sedation. Both key quantities are given
for each of the three dose combinations 3-3 ketodex, 4-2
ketodex and 2-4 ketodex.

R0 = 0.2
R0 = 0.3
R0 = 0.4
R0 = 0.5

0.075

3-3
1
1
1.05

0.070

A
B
C

Proportion of over-sedated participants
among the inadequately sedated participants
3-3 4-2
2-4
0.1 0.01
0.2
0.1 0.01
0.2
0.1 0.01
0.2

0.065

Relative Risk of Adequate Sedation

Average CI Length

Scenario
Letter

350

400

450

500

Sample Size

γ
Probability

0.05
0.83

0.1
0.82

0.15
0.82

0.2
0.83

0.25
0.83

0.3
0.83

Table 3. The probability of randomising the greatest number
of patients to the best dose combination, conditional on
different thresholds for dropping arms with limited evidence of
effectiveness (γ ).

0.608 ensures that 50% of trials declare superiority for
IV ketamine when pD = 0.78. Based on these thresholds,
Table 4 gives the probability of each trial outcome for all the
considered scenarios. The probability of concluding noninferiority is very high at the prior mean of 0.93 and remains
above 90%, provided the true probability of success for
the optimal dose combination is over 0.9. The probability
of an inconclusive trial is high for pD close to the noninferiority threshold. The trial has a higher probability
of being inconclusive if pD is above the non-inferiority
boundary of 0.792. For example, the probability of an
inconclusive trial is approximately 0.5 for both pD = 0.85
Prepared using sagej.cls

Figure 2. The average length of the posterior highest density
credible interval for the four alternative values of R0 , the
proportion of participants randomised the comparator, across
sample size. A black line represents the threshold of 0.07.

and pD = 0.78 (table 4) but 0.85 is further from the noninferiority boundary than 0.78.
The probability of both declaring non-inferiority and
selecting the correct optimal treatment is lower than the
baseline probability of declaring non-inferiority. However,
it is above 77% when pD is above 0.9. This probability is
small as we approach the non-inferiority margin but not
substantially reduced from the underlying probability of
declaring non-inferiority.
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Probability of
Scenario
Number
1
2
3
4
5
6
7
8

pD

Non-inferiority

Inconclusive

Superiority

0.93
0.90
0.87
0.85
0.83
0.792
0.78
0.75

> 0.99
0.93
0.71
0.48
0.27
0.05
0.02
< 0.01

< 0.01
0.07
0.29
0.50
0.66
0.58
0.48
0.22

< 0.01
< 0.01
< 0.01
0.02
0.07
0.37
0.50
0.78

NonInferiority
and Correct
Optimal
Treatment
0.84
0.77
0.61
0.42
0.25
-

Table 4. The operating characteristics of the novel Bayesian design for the Ketodex trial by simulation number (Table 1). We
report the probability of each trial outcome, Non-Inferiority, Inconclusive and Superiority for each of the 8 scenarios we consider.
We also report the probability that the trial simultaneously selects the correct optimal treatment and concludes non-inferiority. We
do not report this value when all three dose combinations are inferior (scenarios 6, 7 and 8). The probability of effectiveness for
the optimal dose combination is listed in the pD column. The complete specification of all probabilities for each scenario is
outlined in Table 1.

Predictive Power
The Bayesian predictive power of the Ketodex trial, i.e.,
the prior probability that the trial is conclusive, is 0.92,
0.92 and 0.94 for scenarios A, B and C, respectively (see
Table 2). The predictive power is higher for scenario C as
the optimal combination was assumed more effective than
the combination seen in the literature. In all scenarios, the
predictive power is over 90%, which is higher than the prior
probability that IN ketodex is superior to IV ketamine. This
is because we can conclude that IV ketamine is superior
to IN ketodex. The predictive power of declaring noninferiority is 0.83, 0.84 and 0.88 for scenarios A, B and C,
respectively.

Discussion
We developed a novel Bayesian trial design that evaluates
the comparative effectiveness of a novel combination
therapy in a non-inferiority framework and determines
the optimal dose combination. We used response adaptive
randomisation to increase the number of participants
receiving the higher performing dose combinations and
dose-response modelling to increase the power of the
comparative effectiveness analysis. This trial minimises
the administrative burden of evaluating novel combination
therapies and, although it is applied to a non-inferiority
setting, can easily be adapted to evaluate superiority of the
novel combination.
Our design has a high chance of reaching the dual study
aims in settings where the probability of effectiveness for
the dose combination is consistent with previous studies.
Note that the Ketodex trial is a non-inferiority trial with
Prepared using sagej.cls

a large non-inferiority margin and, thus, the sample size
requirements for this design may increase substantially
as the non-inferiority margin gets smaller. Furthermore,
the components of this novel design must be re-estimated
in alternative settings, which may change the operating
characteristics. However, we have included all code for this
design in the supplementary material to facilitate the reuse
of this design in other settings.
A limitation of this trial was the decision to restrict ourselves to three dose combinations, rather than investigate
all possible dose combination pairs. This restriction was
made for pragmatic reasons based on clinical judgement,
informed by the literature. 30 However, there is a possibility
that the optimal dose combination is not included in the
combinations investigated in this trial.
This novel design allowed for an inconclusive trial based
on posterior probabilities. To compute these probabilities,
we must have a one-sided test rather than a point
hypothesis. Thus, an adaptation of this decision rule would
be required for two-sided tests. Nonetheless, we included
the possibility of an inconclusive trial outcome based on the
Bayesian trial analysis to encourage the collection of further
information, past the initial completion date of the trial,
if additional data were required to assess the comparative
effectiveness of the two treatments.
Finally, this design and decision making framework
could be used for a seamless dose finding phase II/III trial
for a novel drug. However, this requires a formal assessment
of safety for the novel intervention. 15 The advantage of
dose combination studies is that safety is well understood
so a statistical assessment of safety may not be required,

Heath, et al.

as in the Ketodex trial, although safety should always be
considered by the data safety monitoring board.

Conclusion
We developed a novel trial design to undertake dose
finding and comparative effectiveness analysis that had
good statistical properties and respected the time and
resource constraints of an investigator initiated trial.
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